Kura Oncology, Inc. cash flow statement

In fiscal 2025, Kura Oncology, Inc.'s operations generated −$64.1m of cash; it spent $6.6m on capital projects, leaving free cash flow of −$70.7m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Kura Oncology, Inc.: cash flow statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Cash from operations	−125	134	−64	−112
Depreciation and amortisation	1	1	1	1
Stock-based pay	28	34	37	39
Capital spending	0	0	7	6
Free cash flow	−125	134	−71	−117
Free cash flow after stock pay	−153	100	−108	−156

US$ millions unless shown otherwise. Fiscal quarters.

Kura Oncology, Inc.: cash flow statement, quarterly
Quarter	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Cash from operations	−72	−29	−81	117	−86	−63
Depreciation and amortisation	0	0	0	0	0	0
Stock-based pay	8	7	11	11	8	8
Capital spending	0	1	3	2	0	1
Free cash flow	−72	−30	−83	115	−86	−63
Free cash flow after stock pay	−80	−37	−94	104	−94	−71

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: ADCT vs KURA ASMB vs KURA AAPG vs KURA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Kura Oncology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Kura Oncology, Inc.